BRCA Carriers Have Improved Survival in Ovarian Cancer

This article originally appeared here.
Share this content:
<i>BRCA</i> Carriers Have Improved Survival in Ovarian Cancer
BRCA Carriers Have Improved Survival in Ovarian Cancer

TUESDAY, Jan. 24 (HealthDay News) -- For patients with invasive epithelial ovarian cancer (EOC), BRCA1 and BRCA2 mutations are associated with improved five-year survival, according to a study published in the Jan. 25 issue of the Journal of the American Medical Association.

Kelly L. Bolton, Ph.D., from the National Cancer Institute in Bethesda, Md., and colleagues compared the survival of BRCA carriers and noncarriers with EOC, and investigated survival patterns for BRCA1 and BRCA2 carriers. Data were collected from 26 observational studies, including 909 cases of EOC in BRCA1 carriers, 304 cases in BRCA2 carriers, and 2,666 cases in noncarriers.

The investigators found that the five-year overall survival was 44, 52, and 36 percent in BRCA1 carriers, BRCA2 carriers, and noncarriers, respectively. Carriers of BRCA mutations had more favorable survival than noncarriers after adjustment for study and year of diagnosis. These differences in survival persisted after additional adjustment for age at diagnosis as well as stage, grade, and histology.

"Among patients with invasive EOC, having a germline mutation in BRCA1 or BRCA2 was associated with improved five-year overall survival. BRCA2 carriers had the best prognosis," the authors write.

Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs